S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Estonia to buy US rocket artillery system in $200M deal
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
UK arrests wealthy Russian as police target Putin enablers
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
Hess to buy $750 million in carbon credits from Guyana
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Estonia to buy US rocket artillery system in $200M deal
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
UK arrests wealthy Russian as police target Putin enablers
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
Hess to buy $750 million in carbon credits from Guyana
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Estonia to buy US rocket artillery system in $200M deal
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
UK arrests wealthy Russian as police target Putin enablers
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
Hess to buy $750 million in carbon credits from Guyana
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Estonia to buy US rocket artillery system in $200M deal
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
UK arrests wealthy Russian as police target Putin enablers
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
Hess to buy $750 million in carbon credits from Guyana
NASDAQ:BTAI

BioXcel Therapeutics - BTAI Stock Forecast, Price & News

$18.13
+0.16 (+0.89%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.05
$18.28
50-Day Range
$10.25
$18.13
52-Week Range
$8.80
$24.57
Volume
184,987 shs
Average Volume
258,947 shs
Market Capitalization
$508.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.44

BioXcel Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
189.3% Upside
$52.44 Price Target
Short Interest
Bearish
12.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
1.27mentions of BioXcel Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$411,750 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.31) to ($5.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.84 out of 5 stars

Medical Sector

38th out of 1,034 stocks

Pharmaceutical Preparations Industry

16th out of 502 stocks

BTAI stock logo

About BioXcel Therapeutics (NASDAQ:BTAI) Stock

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Stock News Headlines

Why BioXcel Therapeutics Stock Triumphed This Week
BTAI: Positive Early Metrics for IGALMI™ Launch…
BioXcel Therapeutics, Inc. (BTAI)
SERENITY III Trial to Initiate 2H22
BTAI: SERENITY III Trial to Initiate in 2H22…
BioXcel Therapeutics Misses Q2 EPS by 15c
See More Headlines
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Company Calendar

Last Earnings
11/09/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.44
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+189.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-106,930,000.00
Pretax Margin
-100,052.56%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.53 per share

Miscellaneous

Free Float
17,654,000
Market Cap
$508.00 million
Optionable
Not Optionable
Beta
1.30

Key Executives

  • Dr. Vimal D. Mehta Ph.D. (Age 61)
    Founder, CEO, Pres, & Director
    Comp: $1.41M
  • Dr. Frank D. Yocca Ph.D. (Age 66)
    Sr. VP & Chief Scientific Officer
    Comp: $452.58k
  • Mr. Javier Rodriguez (Age 50)
    Sr. VP, Chief Legal Officer & Corp. Sec.
    Comp: $470.53k
  • Dr. Krishnan Nandabalan Ph.D. (Age 59)
    Chief Digital Officer ?& Director
    Comp: $150k
  • Mr. Richard I. Steinhart MBA (Age 65)
    Sr. VP & CFO
  • Ms. Mary Coleman
    VP of Investment Relations
  • Dr. Iris Francesconi Ph.D.
    Sr. VP of Marketing, Market Research & Commercial Assessments
  • Dr. Vincent J. O'Neill M.D. (Age 53)
    B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer
  • Dr. Cedric Burg
    VP and Head of Global Clinical Operations & Project Management
  • Dr. Chetan D. Lathia Ph.D.
    Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs













BTAI Stock - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTAI shares.
View BTAI analyst ratings
or view top-rated stocks.

What is BioXcel Therapeutics' stock price forecast for 2023?

8 analysts have issued twelve-month price targets for BioXcel Therapeutics' stock. Their BTAI share price forecasts range from $16.00 to $85.00. On average, they predict the company's stock price to reach $52.44 in the next twelve months. This suggests a possible upside of 189.3% from the stock's current price.
View analysts price targets for BTAI
or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2022?

BioXcel Therapeutics' stock was trading at $20.33 at the start of the year. Since then, BTAI stock has decreased by 10.8% and is now trading at $18.13.
View the best growth stocks for 2022 here
.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our BTAI earnings forecast
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its earnings results on Tuesday, November, 9th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.08) by $0.12. During the same period in the previous year, the firm posted ($1.07) earnings per share.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.22%), Artemis Investment Management LLP (4.91%), Vanguard Group Inc. (3.68%), Massachusetts Financial Services Co. MA (1.62%), State Street Corp (1.32%) and Nuveen Asset Management LLC (0.78%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Krishnan Nandabalan, Vimal Mehta and Vincent O'neill.
View institutional ownership trends
.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $18.13.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $508.00 million. The company earns $-106,930,000.00 in net income (profit) each year or ($4.89) on an earnings per share basis.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.

This page (NASDAQ:BTAI) was last updated on 12/4/2022 by MarketBeat.com Staff